Guillermo Garcia-Manero

Guillermo Garcia-Manero leads the MDS program at MD Anderson and is one of the most productive clinical investigators in this field globally. His research has defined optimal use of hypomethylating agents azacitidine and decitabine in high-risk MDS and led to development of oral decitabine/cedazuridine. He has pioneered combination approaches including azacitidine plus venetoclax for higher-risk MDS and studies of novel agents targeting TP53-mutated disease. He has led dozens of clinical trials and trained numerous MDS investigators.